JAMA US FDA recently approved liraglutide to treat type 2 diabetes in combination --- the second glucagon-like peptide-1 (GLP-1) receptor agonist authorized as a generic drug

It's the second GLP-1 generic drug to be approved. But don't get too excited. It's a drug for T2D and is a daily injection. And we are long way from gaining approval of any tirz generic. But this is an example of FDA using its Drug Competition Action Plan --- adopted pursuant to new authority FDA has to move more quickly to approve generics and that helps thwart games drug companies try to play with companies trying to get generics approved. https://jamanetwork.com/journals/jama/fullarticle/2829948?guestAccessKey=f3171dc3-b375-44e0-8c8a-3b90e456dfd2&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jama&utm_content=olf&utm_term=013125&adv=000004304290

These games were addressed in a talk given to FDA by a lawyer-specialist in the area: https://www.fda.gov/media/106393/download Look at some of the examples of what drug companies do to slow down the process of gaining approval to produce a generic.